Integra LifeSciences (IART) Reports In-Line Q4 EPS, Offers FY Guidance

Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.52, in-line with the analyst estimate of $0.52. Revenue for the quarter came in at $255.7 million versus the consensus estimate of $257.27 million.

GUIDANCE:

Integra LifeSciences sees FY2017 EPS of $1.88-$1.94, versus the consensus of $1.93. Integra LifeSciences sees FY2017 revenue of $1.12-1.14 billion, versus the consensus of $1.11 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Taylor Devices (TAYD) Misses Q4 EPS by 31c
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14